However, there is an advanced pipeline of vaccine research currently in clinical and preclinical studies including live-attenuated vaccine candidates as well as virus-vectored and virus-like particle-based vaccines.doi:10.1080/14760584.2020.1775076Usa Thisyakorn...
Usa Thisyakorn, Maria R Capeding, Daniel Yam Thiam Goh, Sri Rezeki Hadinegoro, Zulkifli Ismail, Terapong Tantawichien, Sutee Yoksan, Tikki Pang. (2014) Preparing for dengue vaccine introduction in ASEAN countries: recommendations from the first ADVA regional workshop. Expert Review of Vaccines...
CMAA serves on the Independent Data and Monitoring Committee for ongoing dengue vaccine trials being conducted by Sanofi-Pasteur. Author information Authors and Affiliations Center for Infectious Diseases Research, Instituto Nacional de Salud Pública, Av. Universidad 655. Santa María Ahuacatitlán, Cuern...
In the absence of a vaccine, control of the vector Ae. aegypti was critical in decreasing the burden of dengue in the Americas; however, the initial driving force for this mosquito’s eradication was not dengue, but yellow fever virus [8, 9]. In 1901, William Gorgas, following Walter Ree...
The data presented in this article indicate that immunization with NS1 could provide crucial protection against severe dengue disease and argue for the inclusion in dengue vaccine. Article CAS PubMed Google Scholar Modhiran, N. et al. Dengue virus NS1 protein activates cells via Toll-like ...
Competing interests Yee-Sin Leo was a medical advisor to Sanofi-Pasteur for a dengue vaccine trial. Jeremy Brett was a Sanofi-Pasteur employee. Philippe Buchy is currently an employee of GSK Vaccines. This does not alter the authors' adherence to all the BMC policies on sharing data and ...
China has experienced successive waves of dengue epidemics over the past decade. Nationwide data on 95,339 dengue cases, 89 surveillance sites for mosquito density and population mobility between 337 cities during 2013-20 were extracted. Weekly dengue ti
The tetravalent dengue vaccine strain (TV003/TV005), originally developed by the National Institutes of Health (NIH), USA, has shown promising results in preclinical and clinical trials worldwide. Panacea Biotec, one of three Indian companies to receive the strain, is at ...
vaccine was significantly less neurovirulent than the parental YF-VAX strain [19]. In addition, the vaccine generated seroconversion and strong neutralizing antibody responses against all four DENV serotypes following one administration of either a high or a low dose of the vaccine in cynomolgus ...
Due to the unavailability of an effective vaccine for dengue, one of the best approaches to control the spread of dengue is by managing the vector and its breeding sites. Various strategic approaches have been promoted to control mosquito vectors, including chemical control (indoor residual spraying...